LifeNet Health Corporate | LifeNet Health

Dermacell AWM Featured Publication

In this 2019 study, Dermacell AWM^® was tested in its ability to heal complex diabetic foot ulcers with exposed tendons and/or bone. Deep wounds require advanced treatment because they are difficult to heal. They are rarely included in clinical trials for the study of effective options. This study tackles these complex wounds and finds that Dermacell AWM is effective at rapidly healing complex diabetic foot ulcers.

Supporting Literature

The clinical efficacy of Dermacell AWM is supported by numerous peer-reviewed and published articles in its intended field of use. Dermacell AWM is part of the largest human ADM in chronic wound randomized controlled trial to date, as well as findings by other peer-reviewed and published articles.

Surgeon Perspective

Dr. Zakee O. Shabazz, DPM, discusses his experience using Dermacell AWM when treating stalled healing diabetic foot ulcers. Dermacell AWM is a human acellular dermal matrix (ADM) that serves as a scaffold to reinforce damaged or inadequate soft tissue during wound healing. Dermacell AWM is decellularized using LifeNet Health's proprietary and validated Matracell® decellularization technology -- and is currently the only ADM that meets the definition of decellularization while preserving the extracellular matrix (ECM) that aids in the healing cascade.

Health Economics

The clinical efficacy of Dermacell AWM is supported by a growing number of peer-reviewed, clinical publications. The clinical efficacy of competing grafts has also been shown in the literature. However, information on cost-effectiveness of those grafts has been lacking. Using the most recent cost data, a meta-analysis determined that higher cost does not necessarily correlate with higher rates of healing. Dermacell AWM is an option that is not only clinically efficacious, but cost-effective too.

Non-Clinical Literature

Letter to the Editor: Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix Versus Conventional Care Wound Management and an Active Comparator in the Treatment of Full-Thickness Diabetic Foot Ulcers

Robb GL, Gurtner GC. Eplasty. 2016; 16: e27.

Macrophage phenotypes correspond with remodeling outcomes of various acellular dermal matrices

Case Studies Featuring Dermacell AWM

Beyond peer-reviewed publications, there are a number of case studies supporting the use of Dermacell AWM for treating hard-to-heal wounds. From diabetic foot ulcers, to trauma, and burn reconstruction, Dermacell AWM is effective for complete resolution with one application.

Matracell Decellularization Technology

The Matracell process — utilized in dermal allografts — yields a strong, acellular scaffold that facilitates cell proliferation, cell migration and vascularization. Only tissue processed with Matracell technology meets the threshold of being truly decellularized, minimizing the possibility of an immune response.

The World's Most Advanced ADM for Wounds

Dermacell AWM is a technologically advanced human acellular dermal matrix that is decellularized using Matracell^®, a proprietary, patented, and validated processing technology. Matracell removes a minimum of 97% of donor DNA¹, allowing for rapid cellular infiltration and re-vascularization. Dermacell AWM is terminally sterilized, ready to use without refrigeration or re-hydration.